Enliven Therapeutics, Inc. logo ELVN - Enliven Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 7
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $69.50 DETAILS
HIGH: $80.00
LOW: $59.00
MEDIAN: $69.50
CONSENSUS: $69.50
UPSIDE: 67.31%
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Revenue
Revenue 0 0 0 0 0 0 0 0 0
Cost of Revenue 0.3 0 0 0 0 0 0.0 0 0
Gross Profit (0.3) 0 0 0 0 0 (0.0) 0 0
Operating Expenses
R&D Expenses 85.9 80.8 64.6 31.0 20.5 8.2 19.0 8.2 7.9
SG&A Expenses 33.8 23.8 19.0 7.8 4.3 1.1 5.1 2.4 1.0
Other Expenses 0 0 0 0 0 0 0 0 0
Operating Expenses 119.4 104.6 83.5 38.8 24.8 9.3 24.1 10.7 8.9
Operating Income
Operating Income (119.7) (104.6) (83.5) (38.8) (24.8) (9.3) (24.1) (10.7) (8.9)
Interest Expense 0 0 0 0 0 0 0 0 0
Interest Income 16.0 14.9 12.0 1.1 0.0 0.5 0.6 0 0
Profitability
EBITDA (119.4) (104.2) (83.2) (38.6) (24.6) (9.3) (23.4) (11.3) 0.2
EBIT (119.7) (104.6) (83.5) (38.8) (24.8) (9.3) (23.5) (11.3) 0.2
Income Before Tax (103.7) (88.8) (71.6) (37.7) (24.7) (19.0) (23.5) (11.3) 0.2
Income Tax Expense 0 0.2 0 0 0 0 0 0 0.2
Net Income (103.7) (89.0) (71.6) (37.7) (24.7) (19.0) (23.5) (11.3) 0
Per Share Data
EPS (Basic) -1.83 -1.89 -2.01 -6.03 -3.17 -4.31 -5.43 -2.62
EPS (Diluted) -1.83 -1.89 -2.01 -6.03 -3.17 -4.31 -5.43 -2.62
Shares Outstanding 56.7 47.1 35.5 6.2 7.8 4.4 4.3 4.3 4.3
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Current Assets
Cash & Cash Equivalents 98.9 124.1 100.1 75.5 110.0 47.7 4.9 7.4 9.7
Short-Term Investments 363.7 189.3 153.0 0 0 40.5 24.0 0 0
Net Receivables 0 0 0 0 0 0 0 0 0
Inventory 0 0 0 0 0 0 0 0 0
Other Current Assets 12.3 4.7 10.1 2.2 0 2.2 1.7 0.3 0.6
Total Current Assets 474.9 318.1 266.2 77.8 110.7 90.4 30.6 7.7 10.2
Non-Current Assets
Property, Plant & Equipment 0.4 0.5 1.1 1.5 1.0 0.3 0.4 0 0
Goodwill 0 0 0 0 0 0 0 0 0
Intangible Assets 0 0 0 0 0 0 0 0 0
Long-Term Investments 0 0 0 0.1 0 0 0.1 0 0
Other Non-Current Assets 0.9 7.2 4.7 4.0 1.7 0.1 2.1 0 0
Total Non-Current Assets 1.3 7.6 5.7 5.5 2.7 0.4 2.7 0 0
Total Assets 476.2 325.8 271.9 83.3 113.3 90.8 33.3 7.7 10.2
Current Liabilities
Account Payables 2.2 1.3 0.5 3.4 2.5 2.0 1.7 0.9 0.4
Short-Term Debt 0.4 0 0 0 0 0 0 0 0
Deferred Revenue 0 0 0 5.5 0 0 0 0 0
Other Current Liabilities 14.0 0.2 10.4 0.3 0.2 3.2 1.7 0.8 0.2
Total Current Liabilities 16.6 15.9 25.9 9.7 5.8 6.2 4.2 1.8 0.8
Non-Current Liabilities
Long-Term Debt 0 0 0 0 0 0 0 0 0.7
Deferred Tax Liabilities 0.1 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 0 0 0.1 150.4 0.7 0.2 0.2 32.2 0
Total Non-Current Liabilities 0.1 0 0.1 150.4 0.7 0.2 0.2 32.2 0.7
Total Liabilities 16.7 15.9 26.0 160.1 6.5 6.4 4.4 1.8 1.5
Stockholders' Equity
Common Stock 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Retained Earnings (347.2) (243.5) (154.4) (82.9) (45.2) (96.1) (54.8) (31.3) (20.0)
Accumulated Other Comprehensive Income 0.3 0.1 0.1 (0.1) 0 0.0 0.0 0 0
Total Stockholders' Equity 459.6 309.8 245.9 (76.8) 106.9 84.4 (48.8) (26.3) (15.5)
Total Liabilities & Equity 476.2 325.8 271.9 83.3 113.3 90.8 33.3 7.7 10.2
Debt Metrics
Total Debt 0.4 0 0.3 0.3 0.2 0 0 0 0.7
Net Debt (98.5) (124.1) (99.8) (75.2) (109.9) (47.7) (4.9) (7.4) (9.0)
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017
Operating Activities
Net Income (103.7) (89.0) (71.6) (37.7) (24.7) (19.0) (23.5) (11.3) 0
Depreciation & Amortization 0.3 0.3 0.3 0.2 0.1 0.0 0.0 0 0
Stock-Based Compensation 34.0 20.2 12.9 3.2 1.9 0.1 0.9 0.6 0
Change in Working Capital (1.1) (4.5) 1.4 0.4 3.6 0.6 0.7 1.2 (0.2)
Other Non-Cash Items 0.2 (0.1) (4.3) 1.7 3.8 9.7 0.2 0.8 (7.9)
Operating Cash Flow (70.3) (73.2) (61.3) (32.1) (19.1) (8.5) (21.9) (8.8) (8.8)
Investing Activities
Capital Expenditure (0.2) (0.0) (0.1) (0.6) (0.2) (0.5) (0.1) 0 0
Acquisitions 0 0 0 35 0 0 0 0 0
Purchases of Investments (446.8) (350.7) (268.3) (35) (47.6) (64.2) (23.9) 0 0
Sales/Maturities of Investments 272.9 313.9 120 41.9 45.9 47.5 0 0 0
Other Investing Activities 0.2 0.9 0 (41.9) 1.6 16.7 0 0 0
Investing Cash Flow (173.8) (36.0) (148.4) (0.6) (0.2) (0.5) (24.1) 0 0
Financing Activities
Net Debt Issuance 0 0 0 0 0 0 (2.0) 0 0
Stock Repurchased 0 0 0 0 0 0 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0
Other Financing Activities 0 94.0 73.1 (0.6) 0 33.6 0 6.5 11
Financing Cash Flow 218.9 133.2 234.3 (1.8) (1.0) 130.5 43.6 6.5 11
Cash Position
Net Change in Cash (25.3) 24.0 24.6 (34.5) (20.3) 121.5 (2.4) (2.3) 2.2
Cash at Beginning 124.2 100.2 75.6 110.1 130.4 8.9 7.4 9.7 7.5
Cash at End 98.9 124.2 100.2 75.6 110.1 130.4 4.9 7.4 9.7
Free Cash Flow (70.5) (73.2) (61.4) (32.7) (19.3) (9.0) (22.0) (8.8) (8.8)
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018 2017
Income Statement
Revenue 0 0 0 0 0 0 0 0 0
Gross Profit (0.3) 0 0 0 0 0 (0.0) 0 0
Operating Income (119.7) (104.6) (83.5) (38.8) (24.8) (9.3) (24.1) (10.7) (8.9)
Net Income (103.7) (89.0) (71.6) (37.7) (24.7) (19.0) (23.5) (11.3) 0
EPS (Diluted) -1.83 -1.89 -2.01 -6.03 -3.17 -4.31 -5.43 -2.62
Balance Sheet
Cash & Equivalents 98.9 124.1 100.1 75.5 110.0 47.7 4.9 7.4 9.7
Total Assets 476.2 325.8 271.9 83.3 113.3 90.8 33.3 7.7 10.2
Total Debt 0.4 0 0.3 0.3 0.2 0 0 0 0.7
Stockholders' Equity 459.6 309.8 245.9 (76.8) 106.9 84.4 (48.8) (26.3) (15.5)
Cash Flow
Operating Cash Flow (70.3) (73.2) (61.3) (32.1) (19.1) (8.5) (21.9) (8.8) (8.8)
Capital Expenditure (0.2) (0.0) (0.1) (0.6) (0.2) (0.5) (0.1) 0 0
Free Cash Flow (70.5) (73.2) (61.4) (32.7) (19.3) (9.0) (22.0) (8.8) (8.8)